Providers weigh-in on copay: What's the temperature heading into 2025?
Get exclusive early access to the latest PDR® research on providers' views of manufacturer copay programs, including buy and bill. Understand how they like to learn about copay offers, preferences on sharing information with patients, and more.
New HCP Insights Coming Your Way
As they say, "no landscape evolves like the copay landscape," and at Informa Connect’s 2024 Copay, Reimbursement, and Access Congress November 17-19, Chris Dowd will be sharing exciting new data that truly captures what your important stakeholders, HCPs, are thinking. You'll get year-over-year updates and fresh insights that might just transform how you tackle copay engagement strategies (including buy and bill).
Sign up now to receive the data well before it’s featured in the press or other market news.
Bonus Content
As a bonus, you'll get instant access to our recent whitepaper, "Evidence-Based Approach to Understanding the Benefits of Copay Reduction." It's an approachable guide to the enduring value of pharma copay programs that could wind up fueling discussions around the copay roadmap at your company.
Register & Get Early Access!
.png "Dowd - Chris 2023 (2)")
About Chris Dowd
With a nearly 30-year career spanning leadership roles across Big Pharma, healthcare startups, and the patient support space, Chris Dowd is a forward-looking leader with two clear areas of focus: making specialty medications more affordable and helping people around him succeed. Dowd has been a preeminent voice in patient access and adherence, providing insights into trends such as accumulator adjustment programs, the changing landscape of copay, and digital patient engagement.
A recognized leader in the space, Dowd has been on the forefront of virtually every development in the patient copay industry over the past decade, cofounding the Copay, Reimbursement and Access Congress with CBI in 2012, and since then leading the conference to evolve with the market.
At ConnectiveRx, he leads strategic market analysis and product go-to-market strategies.